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(more than 7 days after hemorrhage). Seizure development 
was not significantly related to mortality risk after correc-
tion for conventional vascular risk factors and hemorrhage 
severity. However, we found a small but independent rela-
tion between the use of anti-epileptic drugs and a lower 
long-term mortality (HR = 0.32, 95% CI 0.11–0.91). In our 
large population, seizures and epilepsy did not relate inde-
pendently to an increased mortality risk after hemorrhage.
Keywords Intracerebral hemorrhage · Seizures · 
Prognosis · Cohort studies
Introduction
Intracerebral hemorrhage (ICH) accounts for roughly 
10–20% of all strokes, and has a 10-year survival of only 
24% [1–4]. Furthermore, survivors of an ICH have a 10% 
risk to develop seizures [5, 6]. These seizures may develop 
within seven days (i.e., early, acute symptomatic seizures), 
or later (i.e., late, remote symptomatic seizures) [7]. The 
development of seizures may inflict additional cerebral 
damage, and hence increase mortality risks after ICH. 
However, seizure development might also coincide with 
important risk factors for mortality (e.g., old age, stroke 
severity, cortical involvement, and alcohol consumption) 
[6, 8, 9].
Previous studies showed conflicting findings with regard 
to the relation between early and late seizures, and mortal-
ity, mostly based on differences in follow-up, definition of 
seizures, number of included patients, and inhomogeneous 
patient populations [6, 10, 12–18]. Furthermore, early, late, 
and recurrent seizures differ in pathogenesis and might also 
have a different relation with mortality [10, 11]. Because 
of the inconclusive evidence, we aimed at defining the 
Abstract Seizures after intracerebral hemorrhage are 
repeatedly seen. Whether the development of seizures 
after intracerebral hemorrhage affects survival in the long 
term is unknown. This study aims to determine the rela-
tion between seizures (i.e., with and without anti-epileptic 
therapy) and long-term mortality risk in a large patient 
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tively included patients with a non-traumatic ICH in all 
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and we assessed all-cause mortality until March 14th 2016. 
Patient who did not survive the first seven days after intrac-
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Cox multivariate analyses to determine independent predic-
tors of mortality. Of 1214 patients, 783 hemorrhagic stroke 
patients fulfilled the inclusion criteria, amongst whom 37 
(4.7%) patients developed early seizures (within 7  days 
after hemorrhage) and 77 (9.8%) developed late seizures 
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long-term mortality risk after ICH in a large population, 
and relate this to post-stroke seizures. We hypothesized that 
the development of seizures negatively influences the sur-
vival of patients after ICH.
Methods
The present study is conducted in accordance with the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE statement) [19].
Participants and study design
We conducted a retrospective cohort study in all three hos-
pitals in the South Limburg region of the Netherlands (i.e., 
hospitals of Maastricht, Sittard, and Heerlen). In agreement 
with the Dutch legislation, approval of the medical ethical 
committees was not necessary. We included all patients 
with a non-traumatic ICH, older than 18  years, between 
January 1st 2004 and December 31st 2009. All intracere-
bral hemorrhages were confirmed with at least CT-imaging 
[20]. We excluded secondary ICH and hemorrhagic trans-
formation of intracerebral infarcts, non-parenchymatous 
hemorrhage (e.g., subdural, epidural, subarachnoid, and 
primary intraventricular hemorrhage), or hemorrhage asso-
ciated with a brain tumor or encephalitis. We also excluded 
patients who did not survive the first seven days to prevent 
information bias, as these patients are not at risk of suffer-
ing from late seizures. Furthermore, we excluded patients 
with pre-existing epilepsy and concurrent use of anti-epi-
leptic drugs, as assessed from records from previous out-
patient department visits, to focus on hemorrhage-associ-
ated seizures.
Variables, data sources and measurements
From hospital electronic patient records, especially look-
ing for entries by neurologists, we retraced the occurrence 
of possible seizures both during hospitalization and dur-
ing post-hospitalization out-patient visits and emergency 
department contacts in the same three hospitals by extract-
ing reports from the treating neurologists. These possible 
seizures were assessed by two independent neurologists 
specialized in epilepsy (MV, RR). Criteria used for the 
assessment were those for seizures with generalized onset 
(e.g., bilateral uncontrolled movements, tonic posture, and/
or loss of consciousness) and seizures with focal onset 
(e.g., hallucinations or cognitive deficits, and motor or sen-
sory symptoms with evidence of seizure progression), and 
classified with the 2014 and 2017 definitions of the Interna-
tional League Against Epilepsy (i.e., ILAE) [21, 22]. Epi-
lepsy was also defined according to ILAE guidelines [21, 
22]. In case of doubt, events were not classified as epileptic 
seizures. We did not routinely use an electroencephalogram 
(EEG), we diagnosed seizures purely clinically. As a cut-off 
point for early seizures (ES) we used seven days, and after 
seven days we classified seizures as late seizures (LS) [23]. 
In case patient had both early and late seizures they would 
be defined as recurrent seizures, but these were analyzed as 
late seizures to maintain sample size.
We obtained the following variables: age at onset of the 
hemorrhage, gender, prior cerebrovascular disease (i.e., 
either ICH, ischemic stroke, or transient ischemic attack), 
vascular comorbidities (i.e., coronary heart disease, hyper-
tension, diabetes mellitus, hypercholesterolemia, peripheral 
vascular disease, as determined by previous diagnosis in 
hospital records), National Institute of Health Stroke Scale 
at admission (NIHSS below 8, NIHSS 8-14, NIHSS above 
14; grouped as described by Adams et  al. [24]), location 
of hemorrhage (i.e., lobar, deep or infratentorial), septum 
shift, use of anticoagulants/antiplatelet drugs (i.e., either 
one, or combinational therapy), and recurrence of hemor-
rhage during follow-up (i.e., a second hemorrhage was not 
recorded as new hemorrhage). Furthermore, prior statin 
use, use of anti-epileptic drugs (AEDs), number of seizures 
before and after start of AEDs, and response to AED ther-
apy were obtained. Municipal inhabitant registry was used 
to record all-cause mortality status for all patients, which is 
a very reliable method in the Netherlands to assess mortal-
ity as all deceased are registered by medical professionals, 
with the latest search dating March 14th 2016.
Statistical analyses
Pearson Chi-square tests were performed to assess differ-
ences amongst seizure groups (no seizures, ES, or LS) in 
categorical data, as was done for continuous data with the 
use of the Student’s t test for normally distributed data and 
the Mann–Whitney U test for non-normally distributed 
data.
Mortality in the different seizure groups was analyzed 
with Kaplan–Meier analyses and log-rank tests, whereas 
we used Cox proportional hazard’s multivariable analysis 
to assess independent predictors of mortality. All variables 
were univariately analyzed and included in the multivari-
ate analyses when significant or previously proven rel-
evant. Cox multivariate analyses were not only performed 
for the complete follow-up, but also for fixed intermedi-
ate intervals (i.e., 2.5, 5, 7.5, and 10  years after onset of 
hemorrhage). This was done to analyze the association 
between seizure development and mortality over time (i.e., 
whether seizures or other predictors are variably associated 
with altered survival rates for different years after ICH). 
We censored patients that did not reach the primary end-
point (mortality) before the last follow-up, dating March 
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14th 2016 (end-of-study censoring). Association measures 
were expressed as hazard ratios (HR), with 95% confidence 
intervals. p values are provided for indication of signifi-
cance, set at a value of p  ≤  0.05. All statistical methods 
were performed using SPSS (SPSS inc. Version 23.0, Chi-
cago, Illinois).
Results
Participants
We identified 1214 ICH patients in this retrospective study, 
and entered these into the selection process (Fig.  1). We 
excluded 393 patients who died within seven days after 
onset of the hemorrhage, 40 because of prior history of epi-
lepsy, and 34 because of missing data: cerebrovascular dis-
ease (n = 1), cardiovascular disease (n = 8), hypertension 
(n = 9), diabetes (n = 5), hypercholesterolemia (n = 15), 
peripheral vascular disease (n = 11), and use of anticoagu-
lants (n = 9) (Fig. 1). The remainder of 747 patients were 
used for all analyses. 641 (86%) patients did not develop 
seizures, 32 (4%) developed only early seizures, whereas 
74 (10%) developed late seizures. Of these 74 patients, 29 
had developed early seizures previously. These patients 
with recurrent seizures were analyzed as late seizures to 
maintain sample size. EEG-confirmation was available in 
26 (20%) patients with late seizures, but none of the early 
seizures were EEG confirmed. Patients that developed 
late seizures mostly received AED therapy (93%). The 
follow-up for seizures and survival status had a median 
duration of 4.8 years (interquartile range of 0–12.6 years). 
Baseline characteristics of the study population are shown 
in Table 1.
Outcome data
During follow-up, 465 (62%) patients died. 400 out of 641 
(62%) died in the NS group, 20 out of 32 (54%) in the ES 
group, and 45 out of 74 (61%) in the LS group. See Fig. 2 
for the Kaplan–Meier plots. The cumulative survival did 
not significantly differ between NS, ES, or LS (Log-rank p 
value 0.58).
Predictors of post‑hemorrhage mortality
We found that relevant predictors of mortality after ICH 
were higher age, male gender, peripheral vascular disease, 
higher NIHSS scores, and use of anticoagulants (i.e., no 
differences between anticoagulants or antiplatelet drugs 
were found) (Table  2). Factor is no longer significant in 
any time interval if statin use is included in the analyses. 
An additional significant predictor of mortality, only in the 
long term (i.e., 7.5 and 10  years), was diabetes mellitus 
(Table 2).
Interestingly, amongst patients with late seizures, the 
use of AEDs did relate to lower mortality rates in the 7.5- 
and 10-year intervals [HR 0.32 (0.11–0.91)]. In this group, 
there was no relation between mortality and the number 
of seizures before initiation of medication, and reaction 
to anti-epileptic drugs. However, the number of patients 
with LS at this long follow-up interval was relatively low 
(n = 35 and n = 7 for 7.5 and 10 years, respectively).
Fig. 1  Selection process as applied in the study. Exclusion was based 
on mortality within the first 7 days, and second, on missing data of 
medical history, given per variable. The final population was divided 
in three groups, group sizes given. ICH intracerebral hemorrhage, 
stroke both ischemic as hemorrhagic, CVD cardiovascular disease, 
HT hypertension, DM diabetes mellitus type 2, PVD peripheral vas-
cular disease, Ac/Ap anticoagulants/antiplatelet drugs, n number of 
patients either excluded or still present in the study, NS no seizures, 
ES early seizures, LS late seizures
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Discussion
Our study underlines that seizures after ICH do not inde-
pendently relate to higher late mortality risks after follow-
up up to 10  years. Mortality was associated with higher 
age, male gender, peripheral vascular disease, higher 
NIHSS scores, and anticoagulant/antiplatelet drug use. 
Mortality in the long term (i.e., 10 years) was also deter-
mined by diabetes mellitus. Overall, we found that 10-year 
survival after ICH was 37% in our population, which was 
not significantly influenced by development of early or late 
seizures.
These results are in line with most [6, 10 13–15, 18], 
but not all [12, 16, 17] studies. These studies showed an 
increased or decreased risk of mortality in patients with 
seizures. Take note that these study populations were 
composed of both ischaemic stroke (IS) and ICH patients, 
and extrapolation should be done carefully though no dif-
ferences between IS and ICH were mentioned. However, 
these previous studies did have significantly shorter peri-
ods of follow-up, and none of these studies found seizures 
to be an independent risk factor of mortality in multivari-
able analyses [12, 16, 18]. The one study that did indicate 
a significant independent relation, and showed a higher 
mortality rate in the seizure group, assessed a heterogene-
ous study population of supposedly vascular events (includ-
ing ischemic stroke, transient ischemic attack and ICH) at 
a young age. However, authors did not specifically include 
ICH patients, and they did not exclude patients not sur-
viving the first seven days after stroke [17]. Up and till 
now, studies with a long-term follow-up, specifically for 
ICH patients, are lacking to the best of our knowledge. 
Table 1  Baseline study characteristics
Study characteristics specified per group (i.e., No seizures (NS), early seizures (ES) or late seizures (LS), mean ± 95% confidence interval (CI) 
for normally distributed continuous variables (i.e., age), median ± interquartile range (IQR) (i.e., for surface and septum shift). Significantly dif-
ferent groups (i.e., p < 0.05) were found for the comparisons NS versus LS (*), NS versus ES (**), or LS versus ES (***)
NIHSS National Institutes of Health Stroke Scale, n.s. not significant in any comparison, N.A. not applicable
Variable NS (n = 641) ES (n = 32) LS (n = 74) p value
Age at hemorrhage in years 72.7 (71.7–73.7) 67.9 (62.6–73.1) 66.2 (62.9–69.5) <0.001*
Gender (male) 339 (52.9%) 17 (53.1%) 43 (58.1%) 0.695
Cerebrovascular disease 175 (27.3%) 7 (21.9%) 18 (24.3%) 0.701
Cardiovascular disease 142 (22.2%) 6 (18.8%) 10 (13.5%) 0.214
Hypertension 392 (61.2%) 17 (53.1%) 38 (51.4%) 0.194
Diabetes mellitus 102 (15.9%) 4 (12.5%) 9 (12.2%) 0.628
Hypercholesterolemia 239 (37.3%) 14 (43.8%) 26 (35.1%) 0.699
Peripheral vascular disease 52 (8.1%) 1 (3.1%) 8 (10.8%) 0.411
NIHSS at admission 0.780
 NIHSS < 8 371 (57.9%) 21 (65.6%) 40 (54.1%)
 NIHSS 8–14 144 (22.5%) 6 (18.8%) 16 (21.6%)
 NIHSS > 14 126 (19.7%) 5 (15.6%) 18 (24.3%)
Location of hemorrhage <0.001*, **
 Lobar 256 (40.0%) 29 (90.6%) 61 (82.4%)
 Deep 326 (50.8%) 3 (9.4%) 10 (13.5%)
 Infratentorial 59 (9.2%) 0 3 (4.1%)
Volume of hemorrhage in  cm3 7.7 ± 21.6 6.7 ± 20.8 21.7 ± 30.4 0.012***
Septum shift mm 0 ± 3.2 0 ± 3.4 0.7 ± 3.7 n.s.
Cause of hemorrhage 57 (8.9%) 5 (15.6%) 12 (16.2%) 0.074
Use of anticoagulants/antiplatelet drugs 339 (52.9%) 12 (37.5%) 35 (47.3%) 0.172
ICH recurrence 58 (9.0%) 2 (6.3%) 13 (17.6%) 0.052
Mortality status at end of follow-up 0.964
 Deceased 400 (62.4%) 20 (62.5%) 45 (60.8%)
 Surviving 241 (37.6%) 12 (37.5%) 29 (39.2%)
EEG alterations N.A. 0 20 (26%) N.A.
AED use 0 0 72 (93%) N.A.
Seizure free before AED N.A. N.A. 36 (49%) N.A.
Seizure free after AED N.A. N.A. 31 (42%) N.A.
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Therefore, our study in ICH patients with a large sample 
size, long-term follow-up, and a selection process designed 
to study the long-term relation between seizures and mor-
tality adds significantly to the existing reports. Our finding 
that mortality is not influenced by seizure development, but 
is mostly determined by age, stroke severity, and vascular 
risk factors might imply that patients may benefit more 
from management of these factors, than from management 
of the seizures.
AED use did correlate, independently from seizure fre-
quency, with lower mortality risks in patients with late 
seizures 7.5 years after hemorrhage. This correlation weak-
ened in the 10-year interval and disappeared in the full 
follow-up, probably due to the limited number of patients 
that already reached that time point. This might suggest 
that AED therapy improves long-term survival after ICH, 
though not likely due to lowered seizures frequencies. Fig. 2  Kaplan–Meier analysis. Cumulative survival time analysis 
(unadjusted), specified on seizure development (i.e., NS, ES, or LS)
Table 2  Multivariable (Cox) analysis; predictors of late mortality
Hazard ratios (±95% CI) for significant covariates in the multivariate Cox survival analysis for the comparison of survival between patients that 
do not develop seizures (no seizures NS), patients that develop seizures within 7 days after the time of hemorrhage onset (early seizures), and 
patients that develop seizures more than 7 days after the time of hemorrhage onset (late seizures LS)
HR hazard ratio, n.s. non-significant, AED anti-epileptic drug
* Maximal follow-up up to 12 years (n = 27; 3.6%)
** No longer significant in any interval if statin use is included
*** Only patients who developed late seizures were given AED
2.5 years censored 
(n = 403)
5 years censored 
(n = 323)
7.5 years censored 
(n = 267)
10 years censored 
(n = 243)
Full follow-
up* censored 
(n = 238)
HR HR HR HR HR
Age at hemorrhage 
(years)
1.06 (1.05–1.08) 1.08 (1.06–1.09) 1.07 (1.06–1.09) 1.08 (1.06–1.08) 1.08 (1.06–1.09)
Gender (male) 1.44 (1.09–1.83) 1.46 (1.15–1.86) 1.35 (1.08–1.68) 1.35 (1.09–1.67) 1.33 (1.07–1.64)
History of cerebrovas-
cular disease
n.s. n.s. n.s. n.s. n.s.
History of cardiovascu-
lar disease
n.s. n.s. n.s. n.s. n.s.
History of hypertension n.s. n.s. n.s. n.s. n.s.
History of diabetes 
mellitus
n.s. n.s. 1.40 (1.07–1.84) 1.37 (1.05–1.79) 1.38 (1.06–1.79)
History of hypercholes-
terolemia**
0.68 (0.50–0.91) 0.75 (0.58–0.96) 0.64 (0.50–0.81) 0.67 (0.53–0.84) 0.69 (0.55–0.87)
History of peripheral 
vascular disease
1.70 (1.07–2.71) 1.78 (1.20–2.65) 1.81 (1.24–2.63) 1.87 (1.30–2.70) 1.87 (1.29–2.69)
NIHSS at admission 1.78 (1.52–2.09) 1.55 (1.35–1.78) 1.55 (1.36–1.77) 1.58 (1.39–1.79) 1.58 (1.39–1.79)
Known cause of hemor-
rhage
n.s. n.s. n.s. n.s. n.s.
Use of anticoagulants 1.56 (1.15–2.11) 1.47 (1.13–1.90) 1.56 (1.22–1.98) 1.45 (1.15–1.82) 1.43 (1.14–1.80)
First recurrence n.s. n.s. n.s. n.s. n.s.
Development of early 
seizures
n.s. n.s. n.s. n.s. n.s.
Development of late 
seizures
n.s. n.s. n.s. n.s. n.s.
AED use*** n.s. n.s. n.s. n.s. n.s.
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There are, however, some caveats, such as the small num-
ber of patients with late seizures that did not receive AED 
therapy (n  =  5). Also, discrepancies in patient treatment 
may play a role in this as patients with worse clinical condi-
tions might not have been treated equally, or even have not 
been treated at all. Though, Gilad et al. found a better neu-
rological outcome after treatment with valproate in patients 
surviving an ICH, which, in combination with our findings, 
suggests a (weakly) positive effect of AED on recovery 
and prognosis after ICH [25]. This finding suggests that 
survival rates might benefit from AED therapy, but further 
research is needed to provide sufficient evidence.
Our study has some limitations. First, despite our large 
population, only 14% of participants developed seizures, 
which somewhat limits the power of this study. Also, there 
is bias due to the retrospective design, though efforts have 
been made to reduce the impact: we minimized the amount 
of missing data using diagnosis codes and hospital stroke 
registries. Furthermore, defining seizures retrospectively 
are another possible source of bias. Patients may under-
report focal seizures or may not seek medical attention or 
overreport, for example, syncopes as seizures. Furthermore, 
subclinical seizures are missed because EEG monitoring 
was not routinely performed, which might lead to under-
estimation of the frequency of seizure development. As a 
consequence of the retrospective design, only survival status 
could be monitored in the period of follow-up after hospi-
tal discharge. Details on seizure severity and post-hospi-
talization comorbidities, which could underlie the associa-
tion between AED therapy and decreased mortality, are not 
known. Furthermore, patients with worse prognosis might 
not have been treated at all. As all of these data are not 
available, these results have to be interpreted with caution.
Notwithstanding these limitations, the strengths of 
our study remain the large sample size allowing enough 
patients to develop early or late seizures, combined with 
the follow-up allowing sufficient time to develop late sei-
zures and determine the long-term survival rates. Also, 
exclusion of patients who deceased during the first seven 
days allows to draw conclusions concerning the mortality 
risk based on seizure development, without interference of 
mortality risks primarily due to the hemorrhage itself.
In conclusion, seizure development does not relate to 
the mortality risk after ICH in our population. However, 
mortality mostly relates to age, stroke severity and vascular 
comorbidities and anticoagulant/antiplatelet use, and there-
fore, these prognostic factors are of value when discussing 
treatment and prognosis after ICH.
 Author contributions DC, acquisition of data, analysis and inter-
pretation of data and drafting of manuscript. KB, acquisition of data, 
interpretation of data, and drafting of manuscript. FS, acquisition of 
data and critical revision of manuscript for intellectual content. BG, 
acquisition of data and critical revision of manuscript for intellectual 
content. MV, acquisition of data and critical revision of manuscript 
for intellectual content. JS, acquisition of data and critical revision of 
manuscript for intellectual content. RO, acquisition of data and criti-
cal revision of manuscript for intellectual content. RR, study concept 
and design, acquisition of data, interpretation of data, study supervi-
sion, and critical revision of manuscript for intellectual content
Compliance with ethical standards 
Conflicts of interest The authors declare to have no conflict of inter-
est.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ikram MA, Wieberdink RG, Koudstaal PJ (2012) International 
epidemiology of intracerebral hemorrhage. Current Atheroscler 
Rep 14(4):300–306
 2. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, 
Connor M, Bennett DA et al (2014) Global and regional burden 
of stroke during 1990–2010: findings from the global burden of 
disease study 2010. Lancet 383(9913):245–254
 3. Sacco S, Marini C, Toni D, Olivieri L, Carolei A (2009) Inci-
dence and 10-year survival of intracerebral hemorrhage in a pop-
ulation-based registry. Stroke 40(2):394–399
 4. Flaherty ML, Haverbusch M, Sekar P, Kissela B, Kleindorfer D, 
Moomaw CJ et al (2006) Long-term mortality after intracerebral 
hemorrhage. Neurology 66(8):1182–1186
 5. Myint PK, Staufenberg EF, Sabanathan K (2006) Post-stroke sei-
zure and post-stroke epilepsy. Postgrad Med J 82(971):568–572
 6. Ferro JM, Pinto F (2004) Poststroke epilepsy: epidemiology, 
pathophysiology and management. Drugs Aging 21(10):639–653
 7. Biffi A, Rattani A, Anderson CD, Ayres AM, Gurol EM et  al 
(2016) Delayed seizures after intracerebral hemorrhage. Brain 
139:2694–2705
 8. Zhang C, Wang X, Wang Y, Zhang JG, Hu W, Ge M et al (2014) 
Risk factors for post-stroke seizures: a systematic review and 
meta-analysis. Epilepsy Res 108(10):1806–1816
 9. Kammersgaard LP, Olsen TS (2005) Poststroke epilepsy in the 
Copenhagen stroke study: incidence and predictors. J Stroke Cer-
ebrovasc Dis. 14(5):210–214
 10. Menon B, Shorvon SD (2009) Ischaemic stroke in adults and 
epilepsy. Epilepsy Res 87(1):1–11
 11. Agrawal A, Timothy J, Pandit L, Manju M (2006) Post-
traumatic epilepsy: an overview. Clin Neurol and Neurosurg 
108(5):433–439
 12. Szaflarski JP, Rackley AY, Kleindorfer DO, Khoury J, Woo D, 
Miller R et al (2008) Incidence of seizures in the acute phase of 
stroke: a population-based study. Epilepsia 49(6):974–981
 13. Hamidou B, Aboa-Eboule C, Durier J, Jacquin A, Lemesle-Mar-
tin M, Giroud M et al (2013) Prognostic value of early epileptic 
seizures on mortality and functional disability in acute stroke: the 
Dijon Stroke Registry (1985–2010). J Neurol 260(4):1043–1051
 14. Mullen MT, Kasner SE, Messe SR (2013) Seizures do not 
increase in-hospital mortality after intracerebral hemorrhage in 
the nationwide inpatient sample. Neurocrit Care 19(1):19–24
1891J Neurol (2017) 264:1885–1891 
1 3
 15. Zelano J, Lundberg RG, Baars L, Hedegard E, Kumlien E (2015) 
Clinical course of poststroke epilepsy: a retrospective nested 
case-control study. Brain Behav 5(9):e00366
 16. Burneo JG, Fang J, Saposnik G (2010) Investigators of the Reg-
istry of the Canadian Stroke Network. Impact of seizures on 
morbidity and mortality after stroke: a Canadian multi-centre 
cohort study. Eur J Neurol 17(1):52–58
 17. Arntz RM, Rutten-Jacobs LC, Maaijwee NA, Schoonder-
waldt HC, Dorresteijn LD, van Dijk EJ et  al (2015) Poststroke 
epilepsy is associated with a high mortality after a stroke at 
young age: follow-up of transient ischemic attack and stroke 
patients and unelucidated risk factor evaluation study. Stroke 
46(8):2309–2311
 18. Reith J, Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS 
(1997) Seizures in acute stroke: predictors and prognostic sig-
nificance. The copenhagen stroke study. Stroke 28(8):1585–1589
 19. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mul-
row CD, Pocock SJ et al (2014) Strengthening the reporting of 
observational studies in epidemiology (STROBE): explanation 
and elaboration. Int J Surg 12(12):1500–1524
 20. de Greef BT, Schreuder FH, Vlooswijk MC, Schreuder AH, 
Rooyer FA, van Oostenbrugge RJ et  al (2015) Early seizures 
after intracerebral hemorrhage predict drug-resistant epilepsy. J 
Neurol 262(3):541–546
 21. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, 
Elger CE et  al (2014) ILAE official report: a practical clinical 
definition of epilepsy. Epilepsia 55(4):475–482
 22. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR et  al 
(2017) ILAE classification of the epilepsies: position paper of 
the ILAE Commission for Classification and Terminology. Epi-
lepsia 58(4):512–521
 23. Guidelines for epidemiologic studies on epilepsy, Commission 
on epidemiology and prognosis (1993) International league 
against epilepsy. Epilepsia 34(4):592–596
 24. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, 
Hacke W (2004) Measuring outcomes as a function of baseline 
severity of ischemic stroke. Cerebrovasc Dis 18(2):124–129
 25. Gilad R, Boaz M, Dabby R, Sadeh M, Lampl Y (2011) Are post 
intracerebral hemorrhage seizures prevented by anti-epileptic 
treatment? Epilepsy Res 95(3):227–231
